Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis
: Background: Cholyl‐lysyl‐fluorescein (CLF) is a fluorescein‐labelled bile acid whose biological behaviour closely resembles that of naturally occurring cholyl glycine. Aim: The aim of this study was to analyze the CLF plasma elimination in patients with liver cirrhosis. Methods: A dose of CLF at 0...
Gespeichert in:
| Veröffentlicht in: | Liver (Copenhagen) 2000-08, Vol.20 (4), p.330-334 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 334 |
|---|---|
| container_issue | 4 |
| container_start_page | 330 |
| container_title | Liver (Copenhagen) |
| container_volume | 20 |
| creator | Milkiewicz, Piotr Saksena, Sushma Cardenas, Teresa Mills, Charles O. Elias, Elwyn |
| description | : Background: Cholyl‐lysyl‐fluorescein (CLF) is a fluorescein‐labelled bile acid whose biological behaviour closely resembles that of naturally occurring cholyl glycine. Aim: The aim of this study was to analyze the CLF plasma elimination in patients with liver cirrhosis. Methods: A dose of CLF at 0.02 mg/kg b.w. was administered i.v. in 26 patients with liver cirrhosis and 9 healthy volunteers. Blood samples were collected before injection and then at 10 min intervals over 60 min. Plasma fluorescence was measured by a luminescence spectrometer and residual fluorescence over the time of the study was compared in each group. Routine liver function tests (rLFTs) were performed before each injection. Results: Plasma elimination of CLF was significantly impaired in patients with cirrhosis compared to healthy subjects with p values |
| doi_str_mv | 10.1034/j.1600-0676.2000.020004330.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72208638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72208638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4480-d618af854a266e4da7774cca9d957383b05aa5149a3f04a41376f5002f4f632c3</originalsourceid><addsrcrecordid>eNqVkE2P0zAQhi0EYkvhLyAfVggOCeP4K0FcULW7rKgKSHwcLa9jqy5uUuyEbf49iVIKVy5j2X7mndGD0CWBnABlr3c5EQAZCCnyAgBymCqjFPLjA7Q4fz5ECyAgsoozeoGepLQDIIJJ_hhdEKh4VZJigepPQae9xjb4vW9059sGtw6bbRuGkIUhjdWFvo02Gesb_HK1vn71Bmt88KHtcOr6esDj-2FstU2X8L3vtjj4XzZi42Pctsmnp-iR0yHZZ6dzib5eX31Zvc_WH29uV-_WmWGshKwWpNSu5EwXQlhWayklM0ZXdcUlLekdcK05YZWmDphmhErhOEDhmBO0MHSJXsy5h9j-7G3q1N6Pa4egG9v2ScmigFKMSUv0dgZNbFOK1qlD9HsdB0VATZbVTk0i1SRSTX7V2bI6ju3PT3P6u72t_2metY7A5QnQyejgom6MT385RkFyMWJXM3bvgx3-awe1vv325zbmZHOOT509nnN0_KGEpJKr75sbxWTxebOqNuoD_Q0Tn6hE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72208638</pqid></control><display><type>article</type><title>Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Milkiewicz, Piotr ; Saksena, Sushma ; Cardenas, Teresa ; Mills, Charles O. ; Elias, Elwyn</creator><creatorcontrib>Milkiewicz, Piotr ; Saksena, Sushma ; Cardenas, Teresa ; Mills, Charles O. ; Elias, Elwyn</creatorcontrib><description>: Background: Cholyl‐lysyl‐fluorescein (CLF) is a fluorescein‐labelled bile acid whose biological behaviour closely resembles that of naturally occurring cholyl glycine. Aim: The aim of this study was to analyze the CLF plasma elimination in patients with liver cirrhosis. Methods: A dose of CLF at 0.02 mg/kg b.w. was administered i.v. in 26 patients with liver cirrhosis and 9 healthy volunteers. Blood samples were collected before injection and then at 10 min intervals over 60 min. Plasma fluorescence was measured by a luminescence spectrometer and residual fluorescence over the time of the study was compared in each group. Routine liver function tests (rLFTs) were performed before each injection. Results: Plasma elimination of CLF was significantly impaired in patients with cirrhosis compared to healthy subjects with p values <0.0001 at each analyzed time point. CLF test showed 100% sensitivity for liver cirrhosis when residual fluorescence was measured 30, 40, 50 and 60 min after injection. Routine LFTs showed 85% sensitivity for bilirubin, 84% for total bile acids, 69% for aspartate aminotransferase 62% for albumin and 50% for alkaline phosphatase. CLF elimination measured 60 min after injection correlated with Child‐Pugh score (r=0.3945; p<0.05) and albumin (rs=0.6451; p<0.001). No adverse reaction or side effects of CLF were observed. Conclusions: CLF test clearly distinguished between the two analyzed groups and was more sensitive than routine liver function tests. The test appears safe, simple to perform and analyze and after validation in larger cohorts of patients may have the potential to become a useful dynamic test of liver function.</description><identifier>ISSN: 0106-9543</identifier><identifier>EISSN: 1600-0676</identifier><identifier>DOI: 10.1034/j.1600-0676.2000.020004330.x</identifier><identifier>PMID: 10959812</identifier><identifier>CODEN: LIVEDR</identifier><language>eng</language><publisher>Copenhagen: Munksgaard International Publishers</publisher><subject>Adult ; Biological and medical sciences ; Cholic Acids - administration & dosage ; Cholic Acids - pharmacokinetics ; cholyl-lysyl-fluorescein ; Female ; Fluoresceins - administration & dosage ; Fluoresceins - pharmacokinetics ; Fluorescent Dyes - administration & dosage ; Fluorescent Dyes - pharmacokinetics ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Injections, Intravenous ; Liver - metabolism ; Liver - pathology ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - metabolism ; liver disease ; Liver Function Tests ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pilot Projects ; plasma elimination ; Reference Values ; Sensitivity and Specificity</subject><ispartof>Liver (Copenhagen), 2000-08, Vol.20 (4), p.330-334</ispartof><rights>2000 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4480-d618af854a266e4da7774cca9d957383b05aa5149a3f04a41376f5002f4f632c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1034%2Fj.1600-0676.2000.020004330.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1034%2Fj.1600-0676.2000.020004330.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1430756$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10959812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Milkiewicz, Piotr</creatorcontrib><creatorcontrib>Saksena, Sushma</creatorcontrib><creatorcontrib>Cardenas, Teresa</creatorcontrib><creatorcontrib>Mills, Charles O.</creatorcontrib><creatorcontrib>Elias, Elwyn</creatorcontrib><title>Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis</title><title>Liver (Copenhagen)</title><addtitle>Liver</addtitle><description>: Background: Cholyl‐lysyl‐fluorescein (CLF) is a fluorescein‐labelled bile acid whose biological behaviour closely resembles that of naturally occurring cholyl glycine. Aim: The aim of this study was to analyze the CLF plasma elimination in patients with liver cirrhosis. Methods: A dose of CLF at 0.02 mg/kg b.w. was administered i.v. in 26 patients with liver cirrhosis and 9 healthy volunteers. Blood samples were collected before injection and then at 10 min intervals over 60 min. Plasma fluorescence was measured by a luminescence spectrometer and residual fluorescence over the time of the study was compared in each group. Routine liver function tests (rLFTs) were performed before each injection. Results: Plasma elimination of CLF was significantly impaired in patients with cirrhosis compared to healthy subjects with p values <0.0001 at each analyzed time point. CLF test showed 100% sensitivity for liver cirrhosis when residual fluorescence was measured 30, 40, 50 and 60 min after injection. Routine LFTs showed 85% sensitivity for bilirubin, 84% for total bile acids, 69% for aspartate aminotransferase 62% for albumin and 50% for alkaline phosphatase. CLF elimination measured 60 min after injection correlated with Child‐Pugh score (r=0.3945; p<0.05) and albumin (rs=0.6451; p<0.001). No adverse reaction or side effects of CLF were observed. Conclusions: CLF test clearly distinguished between the two analyzed groups and was more sensitive than routine liver function tests. The test appears safe, simple to perform and analyze and after validation in larger cohorts of patients may have the potential to become a useful dynamic test of liver function.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cholic Acids - administration & dosage</subject><subject>Cholic Acids - pharmacokinetics</subject><subject>cholyl-lysyl-fluorescein</subject><subject>Female</subject><subject>Fluoresceins - administration & dosage</subject><subject>Fluoresceins - pharmacokinetics</subject><subject>Fluorescent Dyes - administration & dosage</subject><subject>Fluorescent Dyes - pharmacokinetics</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - metabolism</subject><subject>liver disease</subject><subject>Liver Function Tests</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Pilot Projects</subject><subject>plasma elimination</subject><subject>Reference Values</subject><subject>Sensitivity and Specificity</subject><issn>0106-9543</issn><issn>1600-0676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE2P0zAQhi0EYkvhLyAfVggOCeP4K0FcULW7rKgKSHwcLa9jqy5uUuyEbf49iVIKVy5j2X7mndGD0CWBnABlr3c5EQAZCCnyAgBymCqjFPLjA7Q4fz5ECyAgsoozeoGepLQDIIJJ_hhdEKh4VZJigepPQae9xjb4vW9059sGtw6bbRuGkIUhjdWFvo02Gesb_HK1vn71Bmt88KHtcOr6esDj-2FstU2X8L3vtjj4XzZi42Pctsmnp-iR0yHZZ6dzib5eX31Zvc_WH29uV-_WmWGshKwWpNSu5EwXQlhWayklM0ZXdcUlLekdcK05YZWmDphmhErhOEDhmBO0MHSJXsy5h9j-7G3q1N6Pa4egG9v2ScmigFKMSUv0dgZNbFOK1qlD9HsdB0VATZbVTk0i1SRSTX7V2bI6ju3PT3P6u72t_2metY7A5QnQyejgom6MT385RkFyMWJXM3bvgx3-awe1vv325zbmZHOOT509nnN0_KGEpJKr75sbxWTxebOqNuoD_Q0Tn6hE</recordid><startdate>200008</startdate><enddate>200008</enddate><creator>Milkiewicz, Piotr</creator><creator>Saksena, Sushma</creator><creator>Cardenas, Teresa</creator><creator>Mills, Charles O.</creator><creator>Elias, Elwyn</creator><general>Munksgaard International Publishers</general><general>Munksgaard</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200008</creationdate><title>Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis</title><author>Milkiewicz, Piotr ; Saksena, Sushma ; Cardenas, Teresa ; Mills, Charles O. ; Elias, Elwyn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4480-d618af854a266e4da7774cca9d957383b05aa5149a3f04a41376f5002f4f632c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cholic Acids - administration & dosage</topic><topic>Cholic Acids - pharmacokinetics</topic><topic>cholyl-lysyl-fluorescein</topic><topic>Female</topic><topic>Fluoresceins - administration & dosage</topic><topic>Fluoresceins - pharmacokinetics</topic><topic>Fluorescent Dyes - administration & dosage</topic><topic>Fluorescent Dyes - pharmacokinetics</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - metabolism</topic><topic>liver disease</topic><topic>Liver Function Tests</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Pilot Projects</topic><topic>plasma elimination</topic><topic>Reference Values</topic><topic>Sensitivity and Specificity</topic><toplevel>online_resources</toplevel><creatorcontrib>Milkiewicz, Piotr</creatorcontrib><creatorcontrib>Saksena, Sushma</creatorcontrib><creatorcontrib>Cardenas, Teresa</creatorcontrib><creatorcontrib>Mills, Charles O.</creatorcontrib><creatorcontrib>Elias, Elwyn</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Milkiewicz, Piotr</au><au>Saksena, Sushma</au><au>Cardenas, Teresa</au><au>Mills, Charles O.</au><au>Elias, Elwyn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis</atitle><jtitle>Liver (Copenhagen)</jtitle><addtitle>Liver</addtitle><date>2000-08</date><risdate>2000</risdate><volume>20</volume><issue>4</issue><spage>330</spage><epage>334</epage><pages>330-334</pages><issn>0106-9543</issn><eissn>1600-0676</eissn><coden>LIVEDR</coden><abstract>: Background: Cholyl‐lysyl‐fluorescein (CLF) is a fluorescein‐labelled bile acid whose biological behaviour closely resembles that of naturally occurring cholyl glycine. Aim: The aim of this study was to analyze the CLF plasma elimination in patients with liver cirrhosis. Methods: A dose of CLF at 0.02 mg/kg b.w. was administered i.v. in 26 patients with liver cirrhosis and 9 healthy volunteers. Blood samples were collected before injection and then at 10 min intervals over 60 min. Plasma fluorescence was measured by a luminescence spectrometer and residual fluorescence over the time of the study was compared in each group. Routine liver function tests (rLFTs) were performed before each injection. Results: Plasma elimination of CLF was significantly impaired in patients with cirrhosis compared to healthy subjects with p values <0.0001 at each analyzed time point. CLF test showed 100% sensitivity for liver cirrhosis when residual fluorescence was measured 30, 40, 50 and 60 min after injection. Routine LFTs showed 85% sensitivity for bilirubin, 84% for total bile acids, 69% for aspartate aminotransferase 62% for albumin and 50% for alkaline phosphatase. CLF elimination measured 60 min after injection correlated with Child‐Pugh score (r=0.3945; p<0.05) and albumin (rs=0.6451; p<0.001). No adverse reaction or side effects of CLF were observed. Conclusions: CLF test clearly distinguished between the two analyzed groups and was more sensitive than routine liver function tests. The test appears safe, simple to perform and analyze and after validation in larger cohorts of patients may have the potential to become a useful dynamic test of liver function.</abstract><cop>Copenhagen</cop><pub>Munksgaard International Publishers</pub><pmid>10959812</pmid><doi>10.1034/j.1600-0676.2000.020004330.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0106-9543 |
| ispartof | Liver (Copenhagen), 2000-08, Vol.20 (4), p.330-334 |
| issn | 0106-9543 1600-0676 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72208638 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Biological and medical sciences Cholic Acids - administration & dosage Cholic Acids - pharmacokinetics cholyl-lysyl-fluorescein Female Fluoresceins - administration & dosage Fluoresceins - pharmacokinetics Fluorescent Dyes - administration & dosage Fluorescent Dyes - pharmacokinetics Gastroenterology. Liver. Pancreas. Abdomen Humans Injections, Intravenous Liver - metabolism Liver - pathology Liver Cirrhosis - diagnosis Liver Cirrhosis - metabolism liver disease Liver Function Tests Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other diseases. Semiology Pilot Projects plasma elimination Reference Values Sensitivity and Specificity |
| title | Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A23%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20elimination%20of%20cholyl-lysyl-fluorescein%20(CLF):%20a%20pilot%20study%20in%20patients%20with%20liver%20cirrhosis&rft.jtitle=Liver%20(Copenhagen)&rft.au=Milkiewicz,%20Piotr&rft.date=2000-08&rft.volume=20&rft.issue=4&rft.spage=330&rft.epage=334&rft.pages=330-334&rft.issn=0106-9543&rft.eissn=1600-0676&rft.coden=LIVEDR&rft_id=info:doi/10.1034/j.1600-0676.2000.020004330.x&rft_dat=%3Cproquest_cross%3E72208638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72208638&rft_id=info:pmid/10959812&rfr_iscdi=true |